Viridian Therapeutics, Inc.
22.37USD
-0.4500 (-1.97%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on VRDN.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 1.8M | 314.0K | 302.0K | 70.8M | 24.4M | 233.6M |
| Q1 | 216.0K | 98.0K | 72.0K | 72.0K | 141.0K | — |
| Q2 | 256.0K | 72.0K | 72.0K | 75.0K | 284.0K | — |
| Q3 | 1.2M | 72.0K | 86.0K | 70.6M | 4.7M | — |
| Q4 | 105.0K* | 72.0K* | 72.0K* | 132.0K* | 19.3M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -2.22 | -2.91 | — | — | -3.94 | -2.75 |
| Q1 | -.538 | -.883 | -.433 | -1.07 | — | — |
| Q2 | -.581 | -.697 | -.559 | -1.23 | — | — |
| Q3 | -.472 | -.598 | -.631 | — | -1.02 | — |
| Q4 | -.783* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -.819* |
| — |
| — |
| -.952 |
| — |
Debt level and coverage